Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | IGF1R | P08069 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838223 | 0.94 | PTGS2 (0.44) | PTGS2ALDH1A1TSHRMAPTHCAR1 | |
| SCHEMBL4836000 | 0.87 | ATM (0.43) | PTGS2ALDH1A1TSHRMAPTHCAR1 | |
| SCHEMBL4837329 | 0.87 | ATM (0.43) | PTGS2ALDH1A1TSHRMAPTHCAR1 | |
| SCHEMBL4842098 | 0.86 | HPGD (0.42) | PTGS2TSHRHTTATM | |
| SCHEMBL4832753 | 0.86 | SMN1; SMN2 (0.47) | PTGS2TSHRMAPTRAB9ALMNA | |
| SCHEMBL4837510 | 0.86 | ATM (0.39) | ALDH1A1TSHRMAPTHCAR1RAB9A | |
| SCHEMBL1573850 | 0.85 | TSHR (0.50) | ALDH1A1TSHRMAPTHCAR1RAB9A | |
| SCHEMBL4842060 | 0.84 | PTGS2 (0.39) | PTGS2ALDH1A1MAPTHCAR1LMNA | |
| SCHEMBL4842238 | 0.82 | KMT2A (0.39) | PTGS2ALDH1A1MAPTRAB9AGAA | |
| SCHEMBL4832866 | 0.82 | PTGS2 (0.53) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399760-B2 | 1-(4-Methylsulfanyl-phenyl)-6-phenyl-pyrimidin-2,4-(1H)-dione;cyclooxygenase and prostaglandin inhibitor; tumor necrosis factor and interleukins 1, 6, 8, 12 antagonist; | BEXEL PHARMACEUTICALS INC. (US) | 2008-07-15 | — | — | US | claimed |
| US-7101873-B2 | Pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20060194799-A1 | Novel pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-08-31 | — | — | US | claimed |
| US-20040009975-A1 | Novel pyrimidinedione derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-01-15 | — | — | US | claimed |
| WO-2003084937-A2 | PYRIMIDINEDIONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | claimed |
| US-7399760-B2 | 1-(4-Methylsulfanyl-phenyl)-6-phenyl-pyrimidin-2,4-(1H)-dione;cyclooxygenase and prostaglandin inhibitor; tumor necrosis factor and interleukins 1, 6, 8, 12 antagonist; | BEXEL PHARMACEUTICALS INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7101873-B2 | Pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060194799-A1 | Novel pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-20040009975-A1 | Novel pyrimidinedione derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009975-A1 | Novel pyrimidinedione derivatives | TYMS, DPYD, TYMP | PTGS2 1638/4885ALDH1A1 633/4885TSHR 4048/4885 |
| US-20060194799-A1 | Novel pyrimidinedione derivatives | TYMS, TYMP, DPYD | PTGS2 1815/4885ALDH1A1 924/4885TSHR 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.